Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II.

Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74 after presenting safety and biomarker data for

Read the full 411 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers